Anticancer Effect of Radix Astragali on Cholangiocarcinoma In Vitro and Its Mechanism via Network Pharmacology.
Journal
Medical science monitor : international medical journal of experimental and clinical research
ISSN: 1643-3750
Titre abrégé: Med Sci Monit
Pays: United States
ID NLM: 9609063
Informations de publication
Date de publication:
04 Apr 2020
04 Apr 2020
Historique:
entrez:
5
4
2020
pubmed:
5
4
2020
medline:
10
4
2020
Statut:
epublish
Résumé
BACKGROUND This study used network pharmacology method and cell model to assess the effects of Radix Astragali (RA) on cholangiocarcinoma (CCA) and to predict core targets and molecular mechanisms. MATERIAL AND METHODS We performed an in vitro study to assess the effect of RA on CCA using CCK8 assay, the Live-Cell Analysis System, and trypan blue staining. The components and targets of RA were analyzed using the Traditional Chinese Medicine Systems Pharmacology database, and genes associated with CCA were retrieved from the GeneCards and OMIM platforms. Protein-protein interactions were analyzed with the STRING platform. The components-targets-disease network was built by Cytoscape. The TIMER database revealed the expression of core targets with diverse immune infiltration levels. GO and KEGG analyses were performed to identify molecular-biology processes and signaling pathways. The predictions were verified by Western blotting. RESULTS Concentration-dependent antitumor activity was confirmed in the cholangiocarcinoma QBC939 cell line treated with RA. RA contained 16 active compounds, with quercetin and kaempferol as the core compounds. The most important biotargets for RA in CCA were caspase 3, MAPK8, MYC, EGFR, and PARP. The TIMER database revealed that the expression of caspase3 and MYC was related with diverse immune infiltration levels of CCA. The results of Western blotting showed RA significantly influenced the expression of the 5 targets that network pharmacology predicted. CONCLUSIONS RA is an active medicinal material that can be developed into a safe and effective multi-targeted anticancer treatment for CCA.
Identifiants
pubmed: 32246704
pii: 921162
doi: 10.12659/MSM.921162
pmc: PMC7154565
doi:
Substances chimiques
Antineoplastic Agents, Phytogenic
0
Drugs, Chinese Herbal
0
Huang Qi
922OP8YUPF
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e921162Références
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
N Engl J Med. 2008 Mar 13;358(11):1160-74
pubmed: 18337605
Cancer Med. 2018 Apr;7(4):1285-1296
pubmed: 29479816
Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361
pubmed: 27899662
J Clin Oncol. 2007 Sep 10;25(26):4057-65
pubmed: 17827454
Hepatology. 2009 Mar;49(3):860-70
pubmed: 19086036
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
J Cell Biochem. 2013 Apr;114(4):831-43
pubmed: 23097189
Biochem Biophys Res Commun. 2004 Aug 6;320(4):1103-11
pubmed: 15249203
J Biol Chem. 1997 Jul 25;272(30):18530-3
pubmed: 9228015
Pathol Res Pract. 2001;197(2):95-100
pubmed: 11261824
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1461-1467
pubmed: 28756216
Biochim Biophys Acta. 2006 Aug;1766(1):120-39
pubmed: 16889899
Curr Protoc Bioinformatics. 2016 Jun 20;54:1.30.1-1.30.33
pubmed: 27322403
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Biochem J. 2009 Dec 10;424(3):335-45
pubmed: 19788411
Br J Cancer. 2008 Jan 29;98(2):418-25
pubmed: 18087285
Curr Protoc Bioinformatics. 2017 Jun 27;58:1.2.1-1.2.12
pubmed: 28654725
Clin Exp Metastasis. 2008;25(6):685-93
pubmed: 18236164
Mutat Res. 2001 Jun 2;477(1-2):97-110
pubmed: 11376691
Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):553-62
pubmed: 18349272
J Hepatol. 2004 Nov;41(5):808-14
pubmed: 15519654
Int Immunopharmacol. 2019 Jan;66:383-387
pubmed: 30530052
PLoS One. 2016 Mar 09;11(3):e0150235
pubmed: 26960190
J Cell Biochem. 2019 Feb 5;:
pubmed: 30719773
J Ethnopharmacol. 2019 May 10;235:227-242
pubmed: 30703496
J Hepatol. 2014 Aug;61(2):325-32
pubmed: 24704591
Cancer Immun. 2007 Feb 21;7:4
pubmed: 17311363
Gut. 2012 Dec;61(12):1657-69
pubmed: 22895392
Cell Signal. 2006 Dec;18(12):2089-97
pubmed: 16815674
Liver. 1988 Jun;8(3):157-66
pubmed: 2839749
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Cell. 2018 Oct 18;175(3):751-765.e16
pubmed: 30318143
Oncogene. 2012 Mar 15;31(11):1376-88
pubmed: 21822312
Pharmacol Res. 2012 Aug;66(2):105-43
pubmed: 22569528
Cell. 2012 Mar 30;149(1):22-35
pubmed: 22464321
World J Gastroenterol. 2009 Sep 28;15(36):4511-7
pubmed: 19777609
Anticancer Drugs. 1997 Apr;8 Suppl 1:S15-6
pubmed: 9179361
Front Pharmacol. 2017 Jun 26;8:383
pubmed: 28694778
Immunity. 2013 Jul 25;39(1):11-26
pubmed: 23890060
Cancer Cell. 2017 Jun 12;31(6):771-789.e6
pubmed: 28609656
Phytother Res. 2014 Jun;28(6):841-8
pubmed: 24038588
Nutr Cancer. 2016;68(2):250-66
pubmed: 26943884
J Med Invest. 2011 Feb;58(1-2):106-9
pubmed: 21372494
Genome Biol. 2016 Aug 22;17(1):174
pubmed: 27549193
J Clin Oncol. 2012 Jul 20;30(21):2678-83
pubmed: 22711850
Acta Biochim Biophys Sin (Shanghai). 2016 Mar;48(3):238-45
pubmed: 26883800
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
PLoS Med. 2005 Mar;2(3):e73
pubmed: 15737014
Nucleic Acids Res. 2017 Jan 4;45(D1):D331-D338
pubmed: 27899567
Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368
pubmed: 27924014
Cancer. 2008 May 15;112(10):2241-8
pubmed: 18327817
Environ Health Perspect. 2001 Mar;109 Suppl 1:69-75
pubmed: 11250806
Cancer Biother Radiopharm. 1998 Apr;13(2):121-31
pubmed: 10850348
J Hepatol. 2002 Dec;37(6):806-13
pubmed: 12445422
Nat Commun. 2013;4:2612
pubmed: 24113773
J Cheminform. 2014 Apr 16;6:13
pubmed: 24735618
Food Chem. 2013 Jun 15;138(4):2099-107
pubmed: 23497863
Oncologist. 2016 May;21(5):594-9
pubmed: 27000463
Am J Transl Res. 2018 Feb 15;10(2):491-500
pubmed: 29511443
Evid Based Complement Alternat Med. 2013;2013:621423
pubmed: 23762149
Clin Cancer Res. 2007 Mar 1;13(5):1383-8
pubmed: 17332279
Evid Based Complement Alternat Med. 2018 Feb 5;2018:4509892
pubmed: 29636777